Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Challenge Finder aim to become the number 1 place for athletes to find, store and book events. They have built up a platform of over 3000 users and will use the funding for marketing and further development, and are generating revenue through event marketing, advertising and commissions on the bookings.
days to go:
Expired
investment:
£121,510
OpenPlay is a marketplace for sports facilities and activities. It makes it easier for the public to find and book local venues and activities. It has a social layer on top to connect people to each other around their sporting interests and abilities. It makes money via a mixture of a subscription (SAAS) and commission based model for the use of its online bookings and customer management tools. We already have 80,000+ monthly visitors, 100,000+ bookings and over 2,000 venues listed.
days to go:
Expired
investment:
£75,000
Net An Agent is a price comparison site for estate agents. After filling out a few details, you can instantly receive quotes from high-street and online estate agents. When you're ready, you can request a valuation and then pick which agent you'd like to market your property.
days to go:
Expired
investment:
£6,584
PathCloud aims to assemble the global clinical diagnostics resources and data and make them safely available and helpful. The company has created and tested one of the first scalable clinical diagnostics management platforms. It currently has 20,000 clinicians partner networks and 92 registered clinicians. Additionally, it has a network across 48 counties, has over 100 providers, over 3500 diagnostics tests registered and over 10,000 patients by partner telemedicine networks. These funds will be used to gain a significant portion of diagnostics supplier agreements towards the scaling objective, increase efforts towards the international markets and NHS and pursue telemedicine networks.
days to go:
Expired
investment:
£81,720
For those interested in learning to ski or snowboard, Maison Sport allows customers to book private sessions, from a single website, directly with over 350 instructors of which 96% were rated 5 stars. Lessons can take places in more than 130 resorts in France, Italy and Switzerland. A commission fee of 10% per transaction generates revenue and a subscription fee is earned via instructors using the service to schedule lessons and payments.
days to go:
Expired
investment:
£408,857
Muoverti makes patented tilt bikes that bring the real feeling of outdoor cycling to stationary bikes. Their tilting and steering plus digital media control enable exciting, interactive workouts for pros, enthusiasts, and all who like to exercise without getting bored. The connected fitness equipment market is valued at $888 million in 2018. To date, they have attracted investments of more than £600,000 by 30 investors and created 'Planet Fit', a community-driven online platform for games, coaching, and group rides. Funds will be used to build the first 'Alpha' series, finetune the user experience that optimizes the manufacturing process.
days to go:
Expired
investment:
£57,370
